Impact of Mineralocorticoid Receptor Antagonists in the Treatment of Heart Failure: Targeting the Heart Failure Cascade
Epidemiological data from the Indian subcontinent on the burden of Heart failure (HF) is scarce. Mineralocorticoid receptor antagonists (MRAs) are usually used in the management of HF and hypertension. A consortium of experts reviewed and opined on the pathophysiological role of aldosterone in HF an...
Gespeichert in:
| Veröffentlicht in: | Curēus (Palo Alto, CA) CA), 2023-09, Vol.15 (9), p.e45241 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 9 |
| container_start_page | e45241 |
| container_title | Curēus (Palo Alto, CA) |
| container_volume | 15 |
| creator | Jadhav, Uday Nair, Tiny Mohanan, Padhinhare Chopra, Vijay Kerkar, Prafulla Das Biswas, Arup Hazra, Prakash K Zalte, Nitin Sugumaran, Amarnath Mohanasundaram, Senthilnathan |
| description | Epidemiological data from the Indian subcontinent on the burden of Heart failure (HF) is scarce. Mineralocorticoid receptor antagonists (MRAs) are usually used in the management of HF and hypertension. A consortium of experts reviewed and opined on the pathophysiological role of aldosterone in HF and its cascading effects on the heart in terms of cardiac fibrosis, cardiac hypertrophy, and remodeling, increased propensity to cause arrhythmias in addition to its effect on sodium and water retention. This expert opinion document highlights the various mechanisms of action of MRAs. It provides clinical experience and practice-based expert opinion on the use of spironolactone and eplerenone in patients with HF. The role of MRAs in diabetic patients with HF has also been profiled. |
| doi_str_mv | 10.7759/cureus.45241 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10578196</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2878713572</sourcerecordid><originalsourceid>FETCH-LOGICAL-c343t-b03081684a299c39b9b06c952c39358680afa6cba828e8c81d5063241d430ec23</originalsourceid><addsrcrecordid>eNpdkd1LHDEUxUNpqWJ963MJ9KUPrs3HzCTTlyKLX6AIsj6HO5m7a2Qm2SYZxf_euKuifcqF-8vJOTmEfOfsUKm6_W2niFM6rGpR8U9kV_BGzzTX1ed38w7ZT-mOMcaZEkyxr2RHKl21DZe75OF8XIPNNCzppfMYYQg2xOxscD29RovrHCI98hlWwbuUE3We5luki4iQR_Sbq2cIMdMTcEPx84cuIK4wO7_akB-WdA7JQo_fyJclDAn3X849cnNyvJifzS6uTs_nRxczKyuZZx2TTJcgFYi2tbLt2o41tq1FmWWtG81gCY3tQAuN2mre16yR5TP6SjK0Qu6Rv1vd9dSN2NtiuGQ06-hGiI8mgDMfN97dmlW4N5zVSvO2KQq_XhRi-DdhymZ0yeIwgMcwJSO00orLWj0_9vM_9C5M0Zd8hdKlpEYJXqiDLWVjSCni8s0NZ-a5VbNt1WxaLfiP9wne4NcO5RNDG58o</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2884526721</pqid></control><display><type>article</type><title>Impact of Mineralocorticoid Receptor Antagonists in the Treatment of Heart Failure: Targeting the Heart Failure Cascade</title><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Jadhav, Uday ; Nair, Tiny ; Mohanan, Padhinhare ; Chopra, Vijay ; Kerkar, Prafulla ; Das Biswas, Arup ; Hazra, Prakash K ; Zalte, Nitin ; Sugumaran, Amarnath ; Mohanasundaram, Senthilnathan</creator><creatorcontrib>Jadhav, Uday ; Nair, Tiny ; Mohanan, Padhinhare ; Chopra, Vijay ; Kerkar, Prafulla ; Das Biswas, Arup ; Hazra, Prakash K ; Zalte, Nitin ; Sugumaran, Amarnath ; Mohanasundaram, Senthilnathan</creatorcontrib><description>Epidemiological data from the Indian subcontinent on the burden of Heart failure (HF) is scarce. Mineralocorticoid receptor antagonists (MRAs) are usually used in the management of HF and hypertension. A consortium of experts reviewed and opined on the pathophysiological role of aldosterone in HF and its cascading effects on the heart in terms of cardiac fibrosis, cardiac hypertrophy, and remodeling, increased propensity to cause arrhythmias in addition to its effect on sodium and water retention. This expert opinion document highlights the various mechanisms of action of MRAs. It provides clinical experience and practice-based expert opinion on the use of spironolactone and eplerenone in patients with HF. The role of MRAs in diabetic patients with HF has also been profiled.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.45241</identifier><identifier>PMID: 37849613</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Biomarkers ; Cardiology ; Cardiovascular disease ; Diabetes ; Ejection fraction ; Enzymes ; Extracellular matrix ; Heart attacks ; Heart failure ; Hospitalization ; Hypertension ; Internal Medicine ; Kinases ; Mortality ; Peptides</subject><ispartof>Curēus (Palo Alto, CA), 2023-09, Vol.15 (9), p.e45241</ispartof><rights>Copyright © 2023, Jadhav et al.</rights><rights>Copyright © 2023, Jadhav et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2023, Jadhav et al. 2023 Jadhav et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c343t-b03081684a299c39b9b06c952c39358680afa6cba828e8c81d5063241d430ec23</citedby><cites>FETCH-LOGICAL-c343t-b03081684a299c39b9b06c952c39358680afa6cba828e8c81d5063241d430ec23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578196/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578196/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37849613$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jadhav, Uday</creatorcontrib><creatorcontrib>Nair, Tiny</creatorcontrib><creatorcontrib>Mohanan, Padhinhare</creatorcontrib><creatorcontrib>Chopra, Vijay</creatorcontrib><creatorcontrib>Kerkar, Prafulla</creatorcontrib><creatorcontrib>Das Biswas, Arup</creatorcontrib><creatorcontrib>Hazra, Prakash K</creatorcontrib><creatorcontrib>Zalte, Nitin</creatorcontrib><creatorcontrib>Sugumaran, Amarnath</creatorcontrib><creatorcontrib>Mohanasundaram, Senthilnathan</creatorcontrib><title>Impact of Mineralocorticoid Receptor Antagonists in the Treatment of Heart Failure: Targeting the Heart Failure Cascade</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Epidemiological data from the Indian subcontinent on the burden of Heart failure (HF) is scarce. Mineralocorticoid receptor antagonists (MRAs) are usually used in the management of HF and hypertension. A consortium of experts reviewed and opined on the pathophysiological role of aldosterone in HF and its cascading effects on the heart in terms of cardiac fibrosis, cardiac hypertrophy, and remodeling, increased propensity to cause arrhythmias in addition to its effect on sodium and water retention. This expert opinion document highlights the various mechanisms of action of MRAs. It provides clinical experience and practice-based expert opinion on the use of spironolactone and eplerenone in patients with HF. The role of MRAs in diabetic patients with HF has also been profiled.</description><subject>Biomarkers</subject><subject>Cardiology</subject><subject>Cardiovascular disease</subject><subject>Diabetes</subject><subject>Ejection fraction</subject><subject>Enzymes</subject><subject>Extracellular matrix</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Hospitalization</subject><subject>Hypertension</subject><subject>Internal Medicine</subject><subject>Kinases</subject><subject>Mortality</subject><subject>Peptides</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkd1LHDEUxUNpqWJ963MJ9KUPrs3HzCTTlyKLX6AIsj6HO5m7a2Qm2SYZxf_euKuifcqF-8vJOTmEfOfsUKm6_W2niFM6rGpR8U9kV_BGzzTX1ed38w7ZT-mOMcaZEkyxr2RHKl21DZe75OF8XIPNNCzppfMYYQg2xOxscD29RovrHCI98hlWwbuUE3We5luki4iQR_Sbq2cIMdMTcEPx84cuIK4wO7_akB-WdA7JQo_fyJclDAn3X849cnNyvJifzS6uTs_nRxczKyuZZx2TTJcgFYi2tbLt2o41tq1FmWWtG81gCY3tQAuN2mre16yR5TP6SjK0Qu6Rv1vd9dSN2NtiuGQ06-hGiI8mgDMfN97dmlW4N5zVSvO2KQq_XhRi-DdhymZ0yeIwgMcwJSO00orLWj0_9vM_9C5M0Zd8hdKlpEYJXqiDLWVjSCni8s0NZ-a5VbNt1WxaLfiP9wne4NcO5RNDG58o</recordid><startdate>20230914</startdate><enddate>20230914</enddate><creator>Jadhav, Uday</creator><creator>Nair, Tiny</creator><creator>Mohanan, Padhinhare</creator><creator>Chopra, Vijay</creator><creator>Kerkar, Prafulla</creator><creator>Das Biswas, Arup</creator><creator>Hazra, Prakash K</creator><creator>Zalte, Nitin</creator><creator>Sugumaran, Amarnath</creator><creator>Mohanasundaram, Senthilnathan</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230914</creationdate><title>Impact of Mineralocorticoid Receptor Antagonists in the Treatment of Heart Failure: Targeting the Heart Failure Cascade</title><author>Jadhav, Uday ; Nair, Tiny ; Mohanan, Padhinhare ; Chopra, Vijay ; Kerkar, Prafulla ; Das Biswas, Arup ; Hazra, Prakash K ; Zalte, Nitin ; Sugumaran, Amarnath ; Mohanasundaram, Senthilnathan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c343t-b03081684a299c39b9b06c952c39358680afa6cba828e8c81d5063241d430ec23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biomarkers</topic><topic>Cardiology</topic><topic>Cardiovascular disease</topic><topic>Diabetes</topic><topic>Ejection fraction</topic><topic>Enzymes</topic><topic>Extracellular matrix</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Hospitalization</topic><topic>Hypertension</topic><topic>Internal Medicine</topic><topic>Kinases</topic><topic>Mortality</topic><topic>Peptides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jadhav, Uday</creatorcontrib><creatorcontrib>Nair, Tiny</creatorcontrib><creatorcontrib>Mohanan, Padhinhare</creatorcontrib><creatorcontrib>Chopra, Vijay</creatorcontrib><creatorcontrib>Kerkar, Prafulla</creatorcontrib><creatorcontrib>Das Biswas, Arup</creatorcontrib><creatorcontrib>Hazra, Prakash K</creatorcontrib><creatorcontrib>Zalte, Nitin</creatorcontrib><creatorcontrib>Sugumaran, Amarnath</creatorcontrib><creatorcontrib>Mohanasundaram, Senthilnathan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jadhav, Uday</au><au>Nair, Tiny</au><au>Mohanan, Padhinhare</au><au>Chopra, Vijay</au><au>Kerkar, Prafulla</au><au>Das Biswas, Arup</au><au>Hazra, Prakash K</au><au>Zalte, Nitin</au><au>Sugumaran, Amarnath</au><au>Mohanasundaram, Senthilnathan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of Mineralocorticoid Receptor Antagonists in the Treatment of Heart Failure: Targeting the Heart Failure Cascade</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2023-09-14</date><risdate>2023</risdate><volume>15</volume><issue>9</issue><spage>e45241</spage><pages>e45241-</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Epidemiological data from the Indian subcontinent on the burden of Heart failure (HF) is scarce. Mineralocorticoid receptor antagonists (MRAs) are usually used in the management of HF and hypertension. A consortium of experts reviewed and opined on the pathophysiological role of aldosterone in HF and its cascading effects on the heart in terms of cardiac fibrosis, cardiac hypertrophy, and remodeling, increased propensity to cause arrhythmias in addition to its effect on sodium and water retention. This expert opinion document highlights the various mechanisms of action of MRAs. It provides clinical experience and practice-based expert opinion on the use of spironolactone and eplerenone in patients with HF. The role of MRAs in diabetic patients with HF has also been profiled.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>37849613</pmid><doi>10.7759/cureus.45241</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-8184 |
| ispartof | Curēus (Palo Alto, CA), 2023-09, Vol.15 (9), p.e45241 |
| issn | 2168-8184 2168-8184 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10578196 |
| source | PubMed Central Open Access; PubMed Central |
| subjects | Biomarkers Cardiology Cardiovascular disease Diabetes Ejection fraction Enzymes Extracellular matrix Heart attacks Heart failure Hospitalization Hypertension Internal Medicine Kinases Mortality Peptides |
| title | Impact of Mineralocorticoid Receptor Antagonists in the Treatment of Heart Failure: Targeting the Heart Failure Cascade |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T18%3A56%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20Mineralocorticoid%20Receptor%20Antagonists%20in%20the%20Treatment%20of%20Heart%20Failure:%20Targeting%20the%20Heart%20Failure%20Cascade&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Jadhav,%20Uday&rft.date=2023-09-14&rft.volume=15&rft.issue=9&rft.spage=e45241&rft.pages=e45241-&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.45241&rft_dat=%3Cproquest_pubme%3E2878713572%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2884526721&rft_id=info:pmid/37849613&rfr_iscdi=true |